淋球菌耐药性及其研究进展  

Update on the antibiotic resistance in Neisseria gonorrhea

作　　者：于瑞星[1] 陈绍椿[1] 尹跃平[1] 

机构地区：[1]中国医学科学院北京协和医学院皮肤病研究所,南京210042

出　　处：《国际皮肤性病学杂志》2013年第1期55-58,共4页International Journal of Dermatology and Venereology

基　　金：基金项目：国家自然科学基金（81101294）,国家十一五“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项（2008ZX10001-005）

摘　　要：淋球菌是引起人类淋病的病原体，感染后可引起尿道炎、宫颈炎等。淋球菌对抗生素敏感，临床上常使用抗生素治疗淋球菌感染。随着抗生素的使用，淋球菌逐渐对青霉素类、四环素类、喹诺酮类药物产生耐药。目前头孢菌素类药物作为治疗淋球菌感染的一线药物，主要有头孢曲松和头孢克肟等。但引起人们高度关注的是，世界各地均有报道淋球菌对头孢菌素类药物的敏感性逐渐下降，特别是2010年分别在日本、法国和西班牙报道了“超级淋球菌”，因此，临床亟需寻找新的治疗方案。目前世界卫生组织提出各国应根据耐药监测数据制定适合本国淋球菌感染的治疗方案，主要是增加头孢曲松的剂量或者联合用药来治疗淋球菌感染。As the cause of gonorrhea, Neissria gonorrhea （NG） can result in urethritis and cervicitis. NG infection is usually treated by antibiotics in clinical practice. With the wide use of antibiotics in the treatment of NG infection, there have been evidences for increasing resistance to penicillin, tetracycline andquinolones in NG. At present, cephalosporins, mainly including ceftriaxone and cefixime, are the first-line treatment of NG infection. Unfortunately, reducing sensitivity to cephalosporins has been reported in NG worldwide. In 2010, NG strains with high level of resistance to multiple antibiotics, also called NG superbug, were found in Japan, France and Spain. Hence, there is an urgent need to develop new strategies to control NG infection. The World Health Organization has proposed that individualized strategies should be developed for the treatment of NG infection according to surveillance results in different countries. These strategies include increasing the dose of ceftriaxone, combining multiple drugs, etc.

关 键 词：奈瑟淋球菌 淋病 药物耐受性 治疗 

分 类 号：R446[医药卫生—诊断学]